Search Within

Mark Kris

Formats
  1. Journal Article (480)
  2. Meeting Abstract (356)
  3. Conference Paper (16)
  4. Book Section (9)
  5. Review (6)
  6. Guidelines (2)
  7. Editorial (1)
  8. Miscellaneous (1)
  9. Research Letter (1)
Groups
  1. Department of Medicine (872)
  2. Solid Tumor Oncology Division (872)
  3. Thoracic Oncology (872)
  4. Department of Pathology and Laboratory Medicine (319)
  5. GSK Faculty (292)
  6. Human Oncology and Pathogenesis Program (225)

More Groups

People
  1. Gregory Riely (222)
  2. Marc Ladanyi (190)
  3. Vincent Miller (172)
  4. Valerie Rusch (130)
  5. Maria Arcila (123)
  6. Jamie Chaft (107)

More People

Years
  1. 2025 (7)
  2. 2024 (18)
  3. 2023 (27)
  4. 2022 (21)
  5. 2021 (21)
  6. 2020 (25)

More Years

Publications
  1. Journal of Clinical Oncology (235)
  2. Journal of Thoracic Oncology (131)
  3. Clinical Cancer Research (65)
  4. Cancer (33)
  5. Lung Cancer (31)
  6. Annals of Oncology (25)

More Publications

Publishers
  1. American Society of Clinical Oncology (253)
  2. Elsevier Inc. (179)
  3. American Association for Cancer Research (105)
  4. Oxford University Press (48)
  5. Wiley Blackwell (36)
  6. Elsevier Ireland Ltd. (30)

More Publishers

Results (872)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • "A tool, not a crutch': Patients with breast cancers' perceptions of the IBM Watson for Oncology clinical decision support system
    Meeting Abstract

    Hamilton, J. G.; Shuk, E.; Westerman, J. S.; Genoff, M. C.; Werk, R. S.; Pocus, V.; Hay, J. L.; Walters, C.; Elkin, E.; Gucalp, A.; more...
    Annals of Behavioral Medicine (2017)

    Fulltext@MSK | Save
  • Prognostic impact of TTF-1 expression in patients with stage IV lung adenocarcinomas
    Journal Article

    Schilsky, J. B.; Ni, A.; Ahn, L.; Datta, S.; Travis, W. D.; Kris, M. G.; Chaft, J. E.; Rekhtman, N.; Hellmann, M. D.
    Lung Cancer (2017)

    Fulltext@MSK | Save
  • Histologic patterns of lung cancers associated with MET exon 14 splice site alterations (MESSA): A study of 58 Cases
    Meeting Abstract

    Montecalvo, J.; Alex, D.; Lai, V.; Kris, M.; Drilon, A.; Arcila, M. E.; Ladanyi, M.; Rekhtman, N.; Travis, W.
    Modern Pathology (2017)

    Fulltext@MSK | Save
  • Histologic patterns of lung cancers associated with MET exon 14 splice site alterations (MESSA): A study of 58 cases
    Meeting Abstract

    Montecalvo, J.; Alex, D.; Lai, V.; Kris, M.; Drilon, A.; Arcila, M. E.; Ladanyi, M.; Rekhtman, N.; Travis, W.
    Laboratory Investigation (2017)

    Fulltext@MSK | Save
  • A Phase 1/2 trial of ruxolitinib and erlotinib in patients with EGFR-mutant lung adenocarcinomas with acquired resistance to erlotinib
    Journal Article

    Yu, H. A.; Perez, L.; Chang, Q.; Gao, S. P.; Kris, M. G.; Riely, G. J.; Bromberg, J.
    Journal of Thoracic Oncology (2017)

    Fulltext@MSK | Save
  • Concurrent genetic alterations identified by next-generation sequencing in pre-treatment metastatic EGFR-mutant lung cancers
    Meeting Abstract

    Yu, H. A.; Jordan, E.; Ni, A.; Feldman, D.; Rodriguez, C.; Kim, H. R.; Kris, M. G.; Solit, D. B.; Berger, M. F.; Ladanyi, M.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • MDM2 amplification (Amp) to mediate cabozantinib resistance in patients (Pts) with advanced RET-rearranged lung cancers
    Meeting Abstract

    Somwar, R.; Smith, R.; Hayashi, T.; Ishizawa, K.; Charen, A. S.; Khodos, I.; Mattar, M.; He, J.; Balasubramanian, S.; Stephens, P.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Association of outcomes and co-occuring genomic alterations in patients with KRAS-mutant non-small cell lung cancer
    Meeting Abstract

    Riely, G.; Jordan, E.; Kim, H. R.; Yu, H. A.; Berger, M. F.; Solit, D. B.; Kris, M. G.; Ni, A.; Arcila, M. E.; Ladanyi, M.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • A multi-center, randomized, double-blind phase II study comparing temozolomide (TMZ) plus either veliparib (ABT-888), a PARP inhibitor, or placebo as 2nd or 3rd-line therapy for patients (Pts) with relapsed small cell lung cancers (SCLCs)
    Meeting Abstract

    Pietanza, M. C.; Krug, L. M.; Waqar, S. N.; Dowlati, A.; Hann, C. L.; Chiappori, A.; Owonikoko, T. K.; Woo, K.; Bensman, Y.; Hurtado, B.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • A phase I trial of certolizumab plus chemotherapy in patients with stage IV lung adenocarcinomas
    Meeting Abstract

    Paik, P. K.; Eng, J.; Perez, L.; Ritter, E.; Ni, A.; Ng, K. K.; Fiore, J. J.; Wong, P.; Rudin, C. M.; Massague, J.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save